Benefit for All
Benefit for All
Benefit for All
Benefit for All
Designed and Engineered with Heart
Designed and Engineered with Heart
Designed and Engineered
with Heart
Designed and Engineered with Heart
Realhaler
Realhaler
Realhaler
Realhaler
®
®
®
®
Gamechanging Inhaler
Gamechanging Inhaler
Gamechanging Inhaler
Gamechanging Inhaler
Inhalers are lifesaving medical devices commonly prescribed for respiratory conditions such as asthma, COPD, cystic fibrosis, and bronchiectasis.
This innovative new inhaler represents a major breakthrough in inhaled therapies and has the potential to treat conditions such as diabetes, anaphylaxis and viral infections.
Designed for ease of use, it is suitable for patients of all ages and abilities.
The inhaler is both transformable and durable, therefore long-lasting. Its sustainable design not only reduces waste and environmental impact but also lowers costs, helping to make it more affordable and accessible globally.
Inhalers are lifesaving medical devices commonly prescribed for respiratory conditions such as asthma, COPD, cystic fibrosis, and bronchiectasis.
This innovative new inhaler represents a major breakthrough in inhaled therapies and has the potential to treat conditions such as diabetes, anaphylaxis and viral infections.
Designed for ease of use, it is suitable for patients of all ages and abilities. The inhaler is both transformable and durable, therefore long-lasting. Its sustainable design not only reduces waste and environmental impact but also lowers costs, helping to make it more affordable and accessible globally.
Inhalers are lifesaving medical devices commonly prescribed for respiratory conditions such as asthma, COPD, cystic fibrosis, and bronchiectasis.
This innovative new inhaler represents a major breakthrough in inhaled therapies and has the potential to treat conditions such as diabetes, anaphylaxis and viral infections.
Designed for ease of use, it is suitable for patients of all ages and abilities.
The inhaler is both transformable and durable, therefore long-lasting. Its sustainable design not only reduces waste and environmental impact but also lowers costs, helping to make it more affordable and accessible globally.
Inhalers are lifesaving medical devices commonly prescribed for respiratory conditions such as asthma, COPD, cystic fibrosis, and bronchiectasis.
This innovative new inhaler represents a major breakthrough in inhaled therapies and has the potential to treat conditions such as diabetes, anaphylaxis and viral infections.
Designed for ease of use, it is suitable for patients of all ages and abilities. The inhaler is both transformable and durable, therefore long-lasting. Its sustainable design not only reduces waste and environmental impact but also lowers costs, helping to make it more affordable and accessible globally.
Autonomous Care
Easy-to-use
The inhaler is user-friendly for patients with limited lung capacity, or those who struggle with hand-breath coordination. Its comprehensive ergonomic design addresses these challenges effectively.
Sustainable
Traditional single-use inhalers are manufactured with multiple plastic components, or contain harmful propellants. This inhaler is a transformable and durable solution.
Accessible
This inhaler is designed for autonomous care, granting an accessible solution in regions with limited healthcare. Its reusable design and local on-demand manufacturing model makes it affordable worldwide.
This is our approach
Context
Context
Context
Context
This is what we are solving
This is what we are solving
This is what we are solving
This is what we are solving
Challenge
Challenge
Challenge
Challenge
Traditional inhalers require precise coordination and training, making them difficult to use. This often results in wasted medication, increased costs and even potential harm to patients. Due to this, they are not accessible in regions with limited healthcare, making them unaffordable for many people around the world. In addition, most traditional inhalers are single-use and made with multiple plastic components or harmful propellants. This contributes significantly to environmental damage.
Traditional inhalers require precise coordination and training, making them difficult to use. This often results in wasted medication, increased costs and even potential harm to patients. Due to this, they are not accessible in regions with limited healthcare, making them unaffordable for many people around the world. In addition, most traditional inhalers are single-use and made with multiple plastic components or harmful propellants. This contributes significantly to environmental damage.
Traditional inhalers require precise coordination and training, making them difficult to use. This often results in wasted medication, increased costs and even potential harm to patients. Due to this, they are not accessible in regions with limited healthcare, making them unaffordable for many people around the world. In addition, most traditional inhalers are single-use and made with multiple plastic components or harmful propellants. This contributes significantly to environmental damage.
Traditional inhalers require precise coordination and training, making them difficult to use. This often results in wasted medication, increased costs and even potential harm to patients. Due to this, they are not accessible in regions with limited healthcare, making them unaffordable for many people around the world. In addition, most traditional inhalers are single-use and made with multiple plastic components or harmful propellants. This contributes significantly to environmental damage.
Projected value in 2030
Projected value in 2030
Projected value in 2030
Projected value in 2030
€45 / $50 Bn.
€45 / $50 Bn.
€45 / $50 Bn.
€45 / $50 Bn.
Expected market growth
Expected market growth
Expected market growth
Expected market growth
9% Yearly
9% Yearly
9% Yearly
9% Yearly
This is our approach
Autonomous Care
This is our approach
Easy-to-use
Easy-to-use
The inhaler is designed to be user-friendly for patients with limited lung capacity or difficulty coordinating hand and breath movements. Its carefully engineered ergonomic design and optimized fluid dynamics effectively address these challenges.
The inhaler is designed to be user-friendly for patients with limited lung capacity or difficulty coordinating hand and breath movements. Its carefully engineered ergonomic design and optimized fluid dynamics effectively address these challenges.
Sustainable
Sustainable
Traditional single-use inhalers are made with multiple plastic components or contain harmful propellants. In contrast, this inhaler is a transformable and durable solution.
Traditional single-use inhalers are made with multiple plastic components or contain harmful propellants. In contrast, this inhaler is a transformable and durable solution.
Accessible
Accessible
This inhaler is designed for autonomous care, providing an accessible solution is regions with limited healthcare. Its reusable design and local on-demand manufacturing model makes it affordable worldwide.
This inhaler is designed for autonomous care, granting an accessible solution in regions with limited healthcare. Its reusable design and local on-demand manufacturing model makes it affordable worldwide.
Autonomous Care
Roadmap
This is our journey
Roadmap
This is our journey
Roadmap
This is our journey
Roadmap
This is our journey
We have successfully reached key milestones and are now excited to advance into the next phase of our roadmap as we continue working toward our mission.
We have successfully reached key milestones and are now excited to advance into the next phase of our roadmap as we continue working toward our mission.
We have successfully reached key milestones and are now excited to advance into the next phase of our roadmap as we continue working toward our mission.
We have successfully reached key milestones and are now excited to advance into the next phase of our roadmap as we continue working toward our mission.
Conception
Conception
Conception
Conception
Design, engineering, ergonomics and fluid dynamics of the Realhaler are conceptualized and developed
Design, engineering, ergonomics and fluid dynamics of the Realhaler are conceptualized and developed
Design, engineering, ergonomics and fluid dynamics of the Realhaler are conceptualized and developed
Design, engineering, ergonomics and fluid dynamics of the Realhaler are conceptualized and developed
Incorporation of hitaa bv
Incorporation of hitaa bv
Incorporation of hitaa bv
Incorporation of hitaa bv
hitaa BV is incorporated as a med-tech startup for providing innovative and accessible healthcare solutions worldwide
hitaa BV is incorporated as a med-tech startup for providing innovative and accessible healthcare solutions worldwide
hitaa BV is incorporated as a med-tech startup for providing innovative and accessible healthcare solutions worldwide
hitaa BV is incorporated as a med-tech startup for providing innovative and accessible healthcare solutions worldwide
Team of Collaborators
Team of Collaborators
Team of Collaborators
Team of Collaborators
We create a team of collaborators and key experts in pulmonology, fluid dynamics, engineering, invitro-invivo testing and manufacturing.
We create a team of collaborators and key experts in pulmonology, fluid dynamics, engineering, invitro-invivo testing and manufacturing.
We create a team of collaborators and key experts in pulmonology, fluid dynamics, engineering, invitro-invivo testing and manufacturing.
We create a team of collaborators and key experts in pulmonology, fluid dynamics, engineering, invitro-invivo testing and manufacturing.
MITH–2023 and AUMC
MITH–2023 and AUMC
MITH–2023 and AUMC
MITH–2023 and AUMC
· Awarded the MITH Feasibility R&D Grant by the Province of North Holland
· Invited as Honorary Guest Faculty, Pulmonology Department, Amsterdam UMC
· Awarded the MITH Feasibility R&D Grant by the Province of North Holland
· Invited as Honorary Guest Faculty, Pulmonology Department, Amsterdam UMC
· Awarded the MITH Feasibility R&D Grant by the Province of North Holland
· Invited as Honorary Guest Faculty, Pulmonology Department, Amsterdam UMC
· Awarded the MITH Feasibility R&D Grant by the Province of North Holland
· Invited as Honorary Guest Faculty, Pulmonology Department, Amsterdam UMC
Eurostar Eureka and Angel Investors
Eurostar Eureka and Angel Investors
Eurostar Eureka and Angel Investors
Eurostar Eureka and Angel Investors
Currently engaged in the Eurostars Eureka funding application process -the largest international R&D funding programme- and in the process of onboarding angel investors.
Currently engaged in the Eurostars Eureka funding application process -the largest international R&D funding programme- and in the process of onboarding angel investors.
Currently engaged in the Eurostars Eureka funding application process -the largest international R&D funding programme- and in the process of onboarding angel investors.
Currently engaged in the Eurostars Eureka funding application process -the largest international R&D funding programme- and in the process of onboarding angel investors.
Launch
Launch
Launch
Launch
Ongoing development and regulatory pathway: CE certification, FDA approval and HSA registration.
Ongoing development and regulatory pathway: CE certification, FDA approval and HSA registration.
Ongoing development and regulatory pathway: CE certification, FDA approval and HSA registration.
Ongoing development and regulatory pathway: CE certification, FDA approval and HSA registration.
Expansion
Expansion
Expansion
Expansion
Commercialisation across Europe, the Americas, and Southeast Asia.
Commercialisation across Europe, the Americas, and Southeast Asia.
Commercialisation across Europe, the Americas, and Southeast Asia.
Commercialisation across Europe, the Americas, and Southeast Asia.
Experts
Recognizing our work and impact
Experts
Recognizing our work and impact
Experts
Recognizing our work and impact
Experts
Recognizing our work and impact
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed [...] inhaler to [...] reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, elderly patients, and those who are frail [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, NL
Board member SAB and RAPSODI, Member NRS and Longfonds, NL“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed [...] inhaler to [...] reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, elderly patients, and those who are frail [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, NL
Board member SAB and RAPSODI, Member NRS and Longfonds, NL“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed [...] inhaler to [...] reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, elderly patients, and those who are frail [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, NL
Board member SAB and RAPSODI, Member NRS and Longfonds, NL“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed [...] inhaler to [...] reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, elderly patients, and those who are frail [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, NL
Board member SAB and RAPSODI, Member NRS and Longfonds, NL“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed [...] inhaler to [...] reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, elderly patients, and those who are frail [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, NL
Board member SAB and RAPSODI, Member NRS and Longfonds, NL“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed [...] inhaler to [...] reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, elderly patients, and those who are frail [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, NL
Board member SAB and RAPSODI, Member NRS and Longfonds, NL“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed [...] inhaler to [...] reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, elderly patients, and those who are frail [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, NL
Board member SAB and RAPSODI, Member NRS and Longfonds, NL“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed [...] inhaler to [...] reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, elderly patients, and those who are frail [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, NL
Board member SAB and RAPSODI, Member NRS and Longfonds, NL“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed inhaler to reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, old patients, and those who are frail [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, Board member SAB, NRS and Longfonds, NL
“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed inhaler to reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, old patients, and those who are frail [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, Board member SAB, NRS and Longfonds, NL
“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed inhaler to reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, old patients, and those who are frail [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, Board member SAB, NRS and Longfonds, NL
“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
European Respiratory Society
“It would be a game changer in not only providing affordable care in the treatment of respiratory diseases but also in aiding in the combat against climate change [...].”
Netherlands Enterprise Agency RVO
“It is the most needed inhaler to reduce hospitalizations and healthcare costs without a negative environmental impact. It is particularly indicated for children, old patients, and those who are frail [...].”
Dr. Els J.M. Weersink
Department of Respiratory Diseases, Amsterdam UMC, Board member SAB, NRS and Longfonds, NL
“[This novel inhaler] will create a unique collaboration between SMEs, researchers and community participants. Dutch pulmonologists are pleased to participate as Knowledge Users [...].”
Netherlands Enterprise Agency RVO
“The excellent value proposition and the solid IP strategy can ensure sustained competitive advantage in the targeted market niche [...].”
Dr. Don Cockroft
World-renowned respirologist, University of Saskatchewan, Canada
“This novel inhaler has the potential to be a game-changer.”
Netherlands Enterprise Agency RVO
“Excellent quality of the consortium.
Well-outlined and effective plan for commercialisation.
Excellent strategy to gain competitive advantage and facilitate product adoption.
Very good analysis of the technical risks and convincing contingency plan [...].”
®
®
®
®
med-tech startup
med-tech startup
med-tech startup
med-tech startup
About Us
About Us
About Us
About Us
'For years, I’ve been frustrated by how inhalers work, having used them myself since childhood. I’ve witnessed how often they fail many users, especially children and people with fragile health, and then get discarded after just one use. Though I thought about the problem for a long time, during the COVID‑19 period I could develop the concept of the novel inhaler further.'
— S. Pakhalé, CEO, co‑founder, hitaa bv
From the earliest computational fluid dynamics simulations to validating the concept, our work received encouraging feedback from experts. This made it clear that we needed a dedicated entity. That’s how hitaa bv, a med-tech startup, was founded: to bring together a team who shares our zeal to tackle one urgent med-tech issue at a time.
We are a diverse, international team of experts in design, engineering, and healthcare, working in close collaboration with end users and individuals with lived and living experience. Together, we are developing, testing, manufacturing, and preparing to launch an innovative healthcare solution for respiratory conditions.
With great urgency, we are working on our first hitaa product: a transformable, long-lasting, sustainable novel inhaler. Driven by the world’s pressing healthcare needs in a rapidly changing world, our mission is to create and deliver innovative med-tech products, systems, and services that are affordable and accessible to the masses — reducing inequities for the greater good.
Our co-founders and team bring over 25 years of experience in design, engineering, and manufacturing. Guided by social impact, we first demonstrated this approach during the COVID-19 pandemic by developing a Modular Vaccines Carrier to distribute vaccines in remote and inaccessible regions.
Building on that spirit of innovation, we are now determined to deliver this game-changing inhaler, needed by millions. To support and sustain this work, we have incorporated hitaa bv in 2022.
‘Hitaa’, a word from Pali, a proto-Indo-European language, means ‘beneficial for the wider masses’ — a reflection of our core philosophy. We are now actively engaging with investors who share our long-term vision and commitment to impactful healthcare innovations.
'For years, I’ve been frustrated by how inhalers work, having used them myself since childhood. I’ve witnessed how often they fail many users, especially children and people with fragile health, and then get discarded after just one use. Though I thought about the problem for a long time, during the COVID‑19 period I could develop the concept of the novel inhaler further.'
— S. Pakhalé, CEO, co‑founder, hitaa bv
From the earliest computational fluid dynamics simulations to validating the concept, our work received encouraging feedback from experts. This made it clear that we needed a dedicated entity. That’s how hitaa bv, a med-tech startup, was founded: to bring together a team who shares our zeal to tackle one urgent med-tech issue at a time.
We are a diverse, international team of experts in design, engineering, and healthcare, working in close collaboration with end users and individuals with lived and living experience. Together, we are developing, testing, manufacturing, and preparing to launch an innovative healthcare solution for respiratory conditions.
With great urgency, we are working on our first hitaa product: a transformable, long-lasting, sustainable novel inhaler. Driven by the world’s pressing healthcare needs in a rapidly changing world, our mission is to create and deliver innovative med-tech products, systems, and services that are affordable and accessible to the masses — reducing inequities for the greater good.
Our co-founders and team bring over 25 years of experience in design, engineering, and manufacturing. Guided by social impact, we first demonstrated this approach during the COVID-19 pandemic by developing a Modular Vaccines Carrier to distribute vaccines in remote and inaccessible regions.
Building on that spirit of innovation, we are now determined to deliver this game-changing inhaler, needed by millions. To support and sustain this work, we have incorporated hitaa bv in 2022.
‘Hitaa’, a word from Pali, a proto-Indo-European language, means ‘beneficial for the wider masses’ — a reflection of our core philosophy. We are now actively engaging with investors who share our long-term vision and commitment to impactful healthcare innovations.
hitaa bv was born from a personal frustration with current inhalers—devices that often fail users, especially children and people with fragile health, and are discarded after just one use. During the COVID-19 pandemic, our CEO and co-founder, Satyendra Pakhalé, developed the concept of a novel inhaler: a more effective, durable, and user-friendly solution for millions.
Encouraged by early validation and expert feedback, we assembled an international, cross-disciplinary team of designers, engineers, and healthcare professionals. Working closely with end users and individuals with lived respiratory experience, we are now preparing to launch our first product: a transformable, long-lasting, and sustainable inhaler.
Our co-founders and team bring over 25 years of experience in design, engineering, and manufacturing. Guided by social impact, our first response to this mission was the creation of a Modular Vaccine Carrier, developed during the pandemic to reach remote and inaccessible regions. The name ‘hitaa’ comes from Pali, meaning ‘beneficial for the wider masses’ — a reflection of our core philosophy. We are now actively engaging with investors who share our long-term vision and commitment to impactful healthcare innovations.
'For years, I’ve been frustrated by how inhalers work, having used them myself since childhood. I’ve witnessed how often they fail many users, especially children and people with fragile health, and then get discarded after just one use. Though I thought about the problem for a long time, during the COVID‑19 period I could develop the concept of the novel inhaler further.'
— S. Pakhalé, CEO, co‑founder, hitaa bv
From the earliest computational fluid dynamics simulations to validating the concept, our work received encouraging feedback from experts. This made it clear that we needed a dedicated entity. That’s how hitaa bv, a med-tech startup, was founded: to bring together a team who shares our zeal to tackle one urgent med-tech issue at a time.
We are a diverse, international team of experts in design, engineering, and healthcare, working in close collaboration with end users and individuals with lived and living experience. Together, we are developing, testing, manufacturing, and preparing to launch an innovative healthcare solution for respiratory conditions.
With great urgency, we are working on our first hitaa product: a transformable, long-lasting, sustainable novel inhaler. Driven by the world’s pressing healthcare needs in a rapidly changing world, our mission is to create and deliver innovative med-tech products, systems, and services that are affordable and accessible to the masses — reducing inequities for the greater good.
Our co-founders and team bring over 25 years of experience in design, engineering, and manufacturing. Guided by social impact, we first demonstrated this approach during the COVID-19 pandemic by developing a Modular Vaccines Carrier to distribute vaccines in remote and inaccessible regions.
Building on that spirit of innovation, we are now determined to deliver this game-changing inhaler, needed by millions. To support and sustain this work, we have incorporated hitaa bv in 2022.
‘Hitaa’, a word from Pali, a proto-Indo-European language, means ‘beneficial for the wider masses’ — a reflection of our core philosophy. We are now actively engaging with investors who share our long-term vision and commitment to impactful healthcare innovations.
"Making healthcare solutions globally accessible and affordable"
"Making healthcare solutions globally accessible and affordable"
"Making healthcare solutions globally accessible and affordable"
"Making healthcare solutions globally accessible and affordable"
Founders
Founders
Founders
As someone living with asthma, co-founder S. Pakhalé, brings personal insight to the development of a novel inhaler. Drawing on his extensive background in industrial design, engineering, and manufacturing, he transforms lived experience into innovation. The Realhaler reflects his core design values: simplicity, utility, and elegance.
W. Selenowa, co-founder, shares a strong commitment to the common good. With experience across three start-ups, she brings a global perspective and entrepreneurial energy to help make this solution accessible to people around the world.
As someone living with asthma, co-founder S. Pakhalé, brings personal insight to the development of a novel inhaler. Drawing on his extensive background in industrial design, engineering, and manufacturing, he transforms lived experience into innovation. The Realhaler reflects his core design values: simplicity, utility, and elegance.
W. Selenowa, co-founder, shares a strong commitment to the common good. With experience across three start-ups, she brings a global perspective and entrepreneurial energy to help make this solution accessible to people around the world.
As someone living with asthma, co-founder S. Pakhalé, brings personal insight to the development of a novel inhaler. Drawing on his extensive background in industrial design, engineering, and manufacturing, he transforms lived experience into innovation. The Realhaler reflects his core design values: simplicity, utility, and elegance.
W. Selenowa, co-founder, shares a strong commitment to the common good. With experience across three start-ups, she brings a global perspective and entrepreneurial energy to help make this solution accessible to people around the world.
Wera Selenowa
Wera Selenowa
COO, co-founder hitaa bv
COO, co-founder hitaa bv
Managing Director at SPA, Amsterdam since 2010, has broad management experience in arts, design and start-ups. She previously led administration for three Zurich start-ups in e-publishing, pharmaceuticals, and investment. She holds an Executive MBA from the University of Salzburg and a degree in arts management, with work experience in the USA, Germany, and Switzerland.
Managing Director at SPA, Amsterdam since 2010, has broad management experience in arts, design and start-ups. She previously led administration for three Zurich start-ups in e-publishing, pharmaceuticals, and investment. She holds an Executive MBA from the University of Salzburg and a degree in arts management, with work experience in the USA, Germany, and Switzerland.
Satyendra Pakhalé
Satyendra Pakhalé
Satyendra Pakhalé
CEO, co-founder hitaa bv
CEO, co-founder hitaa bv
CEO, co-founder hitaa bv
An internationally acclaimed multi-faceted designer, recognized for successful cross-disciplinary collaborations with global manufacturers, R&D organizations, tech ventures, and cultural and educational institutions worldwide. He brings to this venture his vision of introducing innovative healthcare products to the global community, combined with deep insights and extensive experience in product innovation and manufacturing.
An internationally acclaimed multi-faceted designer, recognized for successful cross-disciplinary collaborations with global manufacturers, R&D organizations, tech ventures, and cultural and educational institutions worldwide. He brings to this venture his vision of introducing innovative healthcare products to the global community, combined with deep insights and extensive experience in product innovation and manufacturing.
An internationally acclaimed multi-faceted designer, recognized for successful cross-disciplinary collaborations with global manufacturers, R&D organizations, tech ventures, and cultural and educational institutions worldwide. He brings to this venture his vision of introducing innovative healthcare products to the global community, combined with deep insights and extensive experience in product innovation and manufacturing.
Wera Selenowa
COO, co-founder hitaa bv
Managing Director at SPA, Amsterdam since 2010, has broad management experience in arts, design and start-ups. She previously led administration for three Zurich start-ups in e-publishing, pharmaceuticals, and investment. She holds an Executive MBA from the University of Salzburg and a degree in arts management, with work experience in the USA, Germany, and Switzerland.
Team
Team
Team
Team
We have created a team of collaborators and key experts in pulmonology, fluid dynamics, industrial design, engineering, invitro-invivo testing and manufacturing.
We have created a team of collaborators and key experts in pulmonology, fluid dynamics, industrial design, engineering, invitro-invivo testing and manufacturing.
We have created a team of collaborators and key experts in pulmonology, fluid dynamics, industrial design, engineering, invitro-invivo testing and manufacturing.
We have created a team of collaborators and key experts in pulmonology, fluid dynamics, industrial design, engineering, invitro-invivo testing and manufacturing.
hitaa bv, Amsterdam, NL | AUMC, Amsterdam, NL | SPA, Amsterdam, NL | Carleton University, Ottawa, Canada
hitaa bv, Amsterdam, NL | AUMC, Amsterdam, NL | SPA, Amsterdam, NL
Carleton University, Ottawa, Canada
hitaa bv, Amsterdam, NL | AUMC, Amsterdam, NL | SPA, Amsterdam, NL | Carleton University, Ottawa, Canada
hitaa bv, Amsterdam, NL
AUMC, Amsterdam, NL
SPA, Amsterdam, NL
Carleton University, Ottawa, Canada
hitaa bv, Amsterdam, NL | AUMC, Amsterdam, NL | SPA, Amsterdam, NL | Carleton University, Ottawa, Canada
Founders
As someone living with asthma, co-founder S. Pakhalé, brings personal insight to the development of a novel inhaler. Drawing on his extensive background in industrial design, engineering, and manufacturing, he transforms lived experience into innovation. The Realhaler reflects his core design values: simplicity, utility, and elegance.
W. Selenowa, co-founder, shares a strong commitment to the common good. With experience across three start-ups, she brings a global perspective and entrepreneurial energy to help make this solution accessible to people around the world.
Satyendra Pakhalé
CEO, co-founder hitaa bv
An internationally acclaimed multi-faceted designer, recognized for successful cross-disciplinary collaborations with global manufacturers, R&D organizations, tech ventures, and cultural and educational institutions worldwide. He brings to this venture his vision of introducing innovative healthcare products to the global community, combined with deep insights and extensive experience in product innovation and manufacturing.
Wera Selenowa
COO, co-founder hitaa bv
Managing Director at SPA, Amsterdam since 2010, has broad management experience in arts, design and start-ups. She previously led administration for three Zurich start-ups in e-publishing, pharmaceuticals, and investment. She holds an Executive MBA from the University of Salzburg and a degree in arts management, with work experience in the USA, Germany, and Switzerland.
Autonomous Care
Easy-to-use
The inhaler is user-friendly for patients with limited lung capacity, or those who struggle with hand-breath coordination. Its comprehensive ergonomic design addresses these challenges effectively.
Sustainable
Traditional single-use inhalers are manufactured with multiple plastic components, or contain harmful propellants. This inhaler is a transformable and durable solution.
Accessible
This inhaler is designed for autonomous care, granting an accessible solution in regions with limited healthcare. Its reusable design and local on-demand manufacturing model makes it affordable worldwide.
This is our approach
Connect
Connect
Connect
Connect
Looking to contribute, support, or invest? We’d love to hear from you!
Looking to contribute, support, or invest? We’d love to hear from you!
Looking to contribute, support, or invest? We’d love to hear from you!
Looking to contribute, support, or invest? We’d love to hear from you!
Empowering Benefits for All
Empowering Benefits for All
Empowering Benefits for All
Empoweri ngBenefits for All
©
©
©
©
The Netherlands
Chambers of Commerce
Kamer van Koophandel
Amsterdam, NL
KVK 85647241
VAT 863695036 B01
® Registered I TM (™) Trademark I SM (℠) Service mark | Copyright © | hitaa bv Amsterdam 2025 All Rights Reserved
The Netherlands
Chambers of Commerce
Kamer van Koophandel
Amsterdam, NL
KVK 85647241
VAT 863695036 B01
The Netherlands
Chambers of Commerce
Kamer van Koophandel
Amsterdam, NL
KVK 85647241
VAT 863695036 B01
® Registered I TM (™) Trademark I SM (℠) Service mark | Copyright © | hitaa bv Amsterdam 2025 All Rights Reserved
® Registered I TM (™) Trademark I SM (℠) Service mark | Copyright © | hitaa bv Amsterdam 2025 All Rights Reserved